Harvard Medical School

SBU microRNA tech sparks $10M anticancer startup

By GREGORY ZELLER // A Stony Brook University-developed technology, a Massachusetts-based startup and an eight-figure investment from China could pave a path toward groundbreaking cancer therapeutics. Through an agreement with the Research Foundation of the State University of New York, a microRNA-manipulating technology developed by SBU biochemist Jingfang Ju has been licensed to Curamir Therapeutics, a startup launched in August on a $10 million stake from Hong Kong-based international innovation financer Delos Capital. Terms of…


For lupus patients, a possible ACE in the hole

By GREGORY ZELLER // A common pharmaceutical treatment for hypertension could be the key to preserving brain function in lupus patients. So says data published this month in the Journal of Experimental Medicine by an international team of scientists led by the redoubtable Betty Diamond, head of the Feinstein Institute for Medical Research’s Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases and a professor of molecular medicine at the Donald and Barbara Zucker School of Medicine…